Download PDF
Thromb Haemost 2024; 124(06): 517-527
DOI: 10.1055/a-2156-7872
Cellular Haemostasis and Platelets

Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity and Noncoding RNAs in Patients with AMI: A Substudy of the PACMAN-AMI Trial

Authors

  • Yasushi Ueki 

    1   Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland

  • Jonas D. Häner

    1   Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland

  • Sylvain Losdat

    2   CTU Bern, University of Bern, Bern, Switzerland

  • Giuseppe Gargiulo

    1   Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland
    3   Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy

  • Hiroki Shibutani

    1   Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland

  • Sarah Bär

    1   Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland

  • Tatsuhiko Otsuka

    1   Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland

  • Raminta Kavaliauskaite

    1   Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland

  • Vera R. Mitter

    4   Institute of Hospital Pharmacy, Bern University Hospital, Bern, Switzerland

  • Fabrice Temperli

    1   Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland

  • David Spirk

    5   Department of Pharmacology, Bern University, Bern and Sanofi, Switzerland

  • Stefan Stortecky

    1   Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland

  • George C. M. Siontis

    1   Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland

  • Marco Valgimigli

    6   Cardiocentro Ticino, Institute and Università della Svizzera Italiana (USI), Lugano, Switzerland

  • Stephan Windecker

    1   Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland

  • Clemens Gutmann

    7   King's British Heart Foundation Centre, King's College London, London, United Kingdom
    8   Division of Cardiology, Medical University of Vienna, Vienna, Austria

  • Konstantinos C. Koskinas

    1   Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland

  • Manuel Mayr

    6   Cardiocentro Ticino, Institute and Università della Svizzera Italiana (USI), Lugano, Switzerland
    7   King's British Heart Foundation Centre, King's College London, London, United Kingdom

  • Lorenz Räber

    1   Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland

Funding This study was supported by a research grant from Bern University Hospital.
Further Information
   Permissions and Reprints


Graphical Abstract

Preview

Comment on:

The Lipid–Platelet Interplay: Unraveling the Effects of PCSK9 Inhibition on Platelet ReactivityThromb Haemost 2024; 124(06): 528-532
DOI: 10.1055/s-0044-1782161

Abstract

Objective The effect of the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor alirocumab on platelet aggregation among patients with acute myocardial infarction (AMI) remains unknown. We aimed to explore the effect of alirocumab added to high-intensity statin therapy on P2Y12 reaction unit (PRU) among AMI patients receiving dual antiplatelet therapy (DAPT) with a potent P2Y12 inhibitor (ticagrelor or prasugrel). In addition, we assessed circulating platelet-derived noncoding RNAs (microRNAs and YRNAs).

Methods This was a prespecified, powered, pharmacodynamic substudy of the PACMAN trial, a randomized, double-blind trial comparing biweekly alirocumab (150 mg) versus placebo in AMI patients undergoing percutaneous coronary intervention. Patients recruited at Bern University Hospital, receiving DAPT with a potent P2Y12 inhibitor, and adherent to the study drug (alirocumab or placebo) were analyzed for the current study. The primary endpoint was PRU at 4 weeks after study drug initiation as assessed by VerifyNow P2Y12 point-of-care assays.

Results Among 139 randomized patients, the majority of patients received ticagrelor DAPT at 4 weeks (57 [86.4%] in the alirocumab group vs. 69 [94.5%] in the placebo group, p = 0.14). There were no significant differences in the primary endpoint PRU at 4 weeks between groups (12.5 [interquartile range, IQR: 27.0] vs. 19.0 [IQR: 30.0], p = 0.26). Consistent results were observed in 126 patients treated with ticagrelor (13.0 [IQR: 20.0] vs. 18.0 [IQR: 27.0], p = 0.28). Similarly, platelet-derived noncoding RNAs did not significantly differ between groups.

Conclusion Among AMI patients receiving DAPT with a potent P2Y12 inhibitor, alirocumab had no significant effect on platelet reactivity as assessed by PRU and platelet-derived noncoding RNAs.

Keywords

acute myocardial infarction - percutaneous coronary intervention - platelet reactivity - proprotein convertase subtilisin/kexin type 9 - microRNA

Supplementary Material



Publication History

Received: 29 April 2023

Accepted: 17 August 2023

Accepted Manuscript online:
18 August 2023

Article published online:
11 September 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany